405 filings
Page 4 of 21
8-K
9ga5six6qm2fd
12 Apr 23
Kineta Announces First Patient Dosed in Phase 1/2 Clinical Study of KVA12123 for Advanced Solid Tumors
7:01am
8-K
5bfbr6
3 Apr 23
Kineta to Present at 22nd Annual Needham Healthcare Conference
7:01am
8-K
3co91xtrv8acdp rkfah
31 Mar 23
Kineta Reports Full Year 2022 Financial Results and Provides Corporate Update
4:03pm
8-K
jb5dodm3ddyng9q cd
31 Mar 23
Regulation FD Disclosure
12:00am
8-K
xs87f
22 Mar 23
Kineta to Present VISTA Biomarker Data at AACR Annual Meeting 2023
7:00am
8-K
ggrhv35nbxr
8 Mar 23
Kineta to Present at the Oppenheimer 33rd Annual Healthcare Conference
7:00am
8-K
acz99g5j
6 Mar 23
Regulation FD Disclosure
7:02am
8-K
3ffe4su
1 Mar 23
Kineta Appoints Internationally-Renowned Clinical Immuno-oncology Experts to its Scientific Advisory Board
4:06pm
8-K
o1rqitbxq whwjh2
24 Feb 23
Departure of Directors or Certain Officers
4:06pm
EFFECT
1wuroma3shmv o307zho
13 Feb 23
Notice of effectiveness
12:00am
POS AM
wrw0eqp
10 Feb 23
Prospectus update (post-effective amendment)
4:54pm
8-K
lztc 233pkn37yp
10 Feb 23
Entry into a Material Definitive Agreement
4:51pm
424B5
hdw2 p50s
10 Feb 23
Prospectus supplement for primary offering
4:48pm
EFFECT
b6uf5zn37g51g3sw1
31 Jan 23
Notice of effectiveness
12:15am
424B4
bdqzf 7niq
30 Jan 23
Prospectus supplement with pricing info
5:02pm
CORRESP
w27w35
26 Jan 23
Correspondence with SEC
12:00am
UPLOAD
e3fnb2fgo
25 Jan 23
Letter from SEC
12:00am
8-K
10yu0 mkkbzzrrw7
5 Jan 23
Regulation FD Disclosure
5:01pm